News Minimalist logo

Wegovy sustains weight loss for at least 4 years

WIRED — May 16, 2024, 12:00 PM UTC

Summary: A study on Wegovy (semaglutide) showed sustained weight loss over four years in 17,604 participants without diabetes. The drug led to an average weight loss of 10.2% compared to a placebo group's 1.5%, with a treatment difference of 8.7%. The SELECT trial found that 52.4% of those on semaglutide moved to a lower BMI category. Researchers suggest broad use of semaglutide for overweight individuals with cardiovascular disease.

Full article

Article metrics

The article metrics are deprecated.

I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.

Timeline:

  1. [4.7]
    New therapy targets brain's appetite center for weight loss (News-Medical.Net)
    114d 4h
    Source
  2. [4.4]
    Dual-action drug MK-801 doubles weight loss in mice (Inside Precision Medicine)
    114d 7h
    Source
  3. [2.9]
    New weight loss shot CT-388 shows promising results (Daily Mail)
    114d 7h
    Source
  4. [5.5]
    Roche's CT-388 weight loss drug shows promising trial results (CNBC)
    114d 9h

    ScoresSource
  5. [2.1]
    Novo Nordisk to study Ozempic's effects on alcohol consumption (CNN)
    115d 1h
    Source
  6. [5.5]
    Semaglutides improve heart health by 20% beyond weight loss (The Guardian)
    115d 13h

    ScoresSource
  7. [4.5]
    Personalized semaglutide dosing aids sustainable weight loss (News-Medical.Net)
    116d 5h
    Source
  8. [3.2]
    Ozempic reduces heart attack risk, may help fight other diseases (Daily Mail)
    116d 5h
    Source
  9. [5.2]
    Semaglutide (Ozempic) shows potential for treating addiction and dementia (The Guardian)
    116d 6h

    ScoresSource
  10. [3.0]
    New weight loss jab retatrutide shows promising results (Daily Mail)
    116d 7h
    Source
  11. [3.1]
    "Book 'Magic Pill' delves into weight loss drug Ozempic." (Mint)
    116d 10h
    Source
  12. [5.8]
    Semaglutide reduces heart attack risk by 20% (Irish Examiner)
    116d 12h

    ScoresSource
  13. [5.8]
    Semaglutide reduces heart attack risk by 20% (The Guardian)
    116d 23h

    ScoresSource
  14. [4.2]
    Wegovy trial shows 10% weight loss maintained after 4 years (CTV News)
    116d 23h
    Source
  15. [5.1]
    Wegovy's long trial shows sustained 10% weight loss, heart protection (CNN)
    117d 0h

    ScoresSource
  16. [4.6]
    Semaglutide reduces need for diuretics in heart failure patients (Diagnostic and Interventional Cardiology)
    117d 6h
    Source
  17. [3.9]
    Semaglutide improves heart failure symptoms and reduces diuretic dose (News-Medical.Net)
    117d 6h
    Source
  18. [4.5]
    Author suggests India learn from Japan's diet success, caution on weight-loss drugs (BusinessLine)
    117d 19h
    Source
  19. [2.2]
    1 in 8 US adults use GLP-1 drugs like Ozempic (CNN)
    120d 12h
    Source
  20. [3.1]
    Wegovy weight loss drug now available in Canada (CTV News Kitchener)
    122d 2h
    Source